Xpert MTB/RIF Ultra 诊断 HIV 相关结核性脑膜炎的前瞻性验证研究
本研究在乌干达两家医院前瞻性纳入 204 例疑似脑膜炎的成人 HIV 阳性患者,评估 Xpert Ultra 检测脑脊液诊断结核性脑膜炎的性能。
要点
- Xpert Ultra 诊断 HIV 相关结核性脑膜炎的灵敏度高于 Xpert 和 MGIT 培养。
- Xpert Ultra 阴性预测值约 93%,阴性结果不能排除结核性脑膜炎。
- 临床判断和新型高灵敏度即时检测仍是必要的。
核心结论
- 在 HIV 阳性疑似脑膜炎人群中,Xpert Ultra 检测脑脊液诊断结核性脑膜炎的灵敏度高于 Xpert 和 MGIT 培养。
研究设计与样本
- 前瞻性验证研究,在乌干达 Mulago 国家转诊医院和 Mbarara 地区转诊医院纳入疑似脑膜炎的成人。
- 以 probable 或 definite 结核性脑膜炎的统一临床病例定义和复合微生物学参考标准评估诊断性能。
主要发现
- Xpert Ultra 检出 9 例 Xpert 和 MGIT 培养均漏诊的结核性脑膜炎病例。
临床怎么用
- 在 HIV 阳性疑似结核性脑膜炎患者中,Xpert Ultra 可作为脑脊液快速病原学检测,灵敏度优于 Xpert 和 MGIT 培养。
- Xpert Ultra 阴性结果不能排除结核性脑膜炎,需结合临床判断,必要时启动经验性治疗。
局限性
- 研究限于乌干达 HIV 阳性成人疑似脑膜炎人群,外推至其他地区或 HIV 阴性人群需谨慎。
- 统一临床病例定义和复合微生物学参考标准可能影响诊断性能评估的准确性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Tuberculous meningitis accounts for 1-5% of tuberculosis cases. Diagnostic delay contributes to poor outcomes. We evaluated the performance of the new Xpert MTB/RIF Ultra (Xpert Ultra) for tuberculous meningitis diagnosis. METHODS: In this prospective validation study, we tested the cerebrospinal fluid (CSF) of adults presenting with suspected meningitis (ie, headache or altered mental status with clinical signs of meningism) to the Mulago National Referral Hospital and Mbarara Regional Referral Hospital in Uganda. We centrifuged the CSF, resuspended the cell pellet in 2 mL CSF, and tested 0·5 mL aliquots with Xpert Ultra, Xpert MTB/RIF (Xpert), and mycobacterial growth indicator tube (MGIT) culture. We quantified diagnostic performance against the uniform case definition of probable or definite tuberculous meningitis and a composite microbiological reference standard. FINDINGS: From Nov 25, 2016, to Jan 24, 2019, we screened 466 adults with suspected meningitis and tested 204 for tuberculous meningitis. Uniform clinical case definition classified 51 participants as having probable or definite tuberculous meningitis. Against this uniform case definition, Xpert Ultra had 76·5% sensitivity (95% CI 62·5-87·2; 39 of 51 patients) and a negative predictive value of 92·7% (87·6-96·2; 153 of 165), compared with 55·6% sensitivity (44·0-70·4; 25 of 45; p=0·0010) and a negative predictive value of 85·8% (78·9-91·1; 121 of 141) for Xpert and 61·4% sensitivity (45·5-75·6; 27 of 44; p=0·020) and negative predictive value of 85·2% (77·4-91·1; 98 of 115) for MGIT culture. Against the composite microbiological reference standard, Xpert Ultra had sensitivity of 92·9% (80·5-98·5; 39 of 42), higher than Xpert at 65·8% (48·6-80·4; 25 of 38; p=0·0063) and MGIT culture at 72·2% (55·9-86·2; 27 of 37; p=0·092). Xpert Ultra detected nine tuberculous meningitis cases missed by Xpert and MGIT culture. INTERPRETATION: Xpert Ultra detected tuberculous meningitis with higher sensitivity than Xpert and MGIT culture in this HIV-positive population. However, with a negative predictive value of 93%, Xpert Ultra cannot be used as a rule-out test. Clinical judgment and novel highly sensitive point-of-care tests are still required. FUNDING: Wellcome Trust, National Institute of Health, National Institute of Neurologic Diseases and Stroke, Fogarty International Center, and National Institute of Allergy and Infectious Diseases.
引用
- Cresswell FV, Tugume L, Bahr NC, et al. Xpert MTB/RIF Ultra for the diagnosis of HIV-associated tuberculous meningitis: a prospective validation study. Lancet Infect Dis. 2020. PMID: 31924549. doi:10.1016/S1473-3099(19)30550-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。